retatrutide peptide trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II retatrutide peptide clinical trial 16mg

Many patients wonder whether they can discontinue GLP-1 medications like semaglutide after reaching their weight loss goals

There is a complex intimate relationship between elevated plasma TMAO concentration and renal dysfunction and intestinal microbiota Dysbiosis in CKD patients

Holst JJ, Albrechtsen NJ, Gabe MB, Rosenkilde MM

Prioritize protein and fiber, limit high-fat heavy meals if nausea occurs, and maintain hydration

How do the potential benefits of GLP-1 agonists in reducing risks of heart and kidney disease compare with the risks of side effects like hypoglycemia or gallbladder disorders, and how should a clinician balance these considerations